Rxivist logo

Somatic mutations in cytosolic or mitochondrial isoforms of isocitrate dehydrogenase (IDH1 or IDH2, respectively) contribute to oncogenesis via production of the metabolite 2-hydroxyglutarate (2HG). Isoform-selective IDH inhibitors suppress 2HG production and induce clinical responses in patients with IDH1- and IDH2-mutant malignancies. Despite the promising activity of IDH inhibitors, the mechanisms that mediate resistance to IDH inhibition are poorly understood. Here, we describe four clinical cases that identify mutant IDH isoform switching, either from mutant IDH1 to mutant IDH2 or vice versa, as a mechanism of acquired clinical resistance to IDH inhibition in solid and liquid tumors.

Download data

  • Downloaded 516 times
  • Download rankings, all-time:
    • Site-wide: 70,278
    • In cancer biology: 2,038
  • Year to date:
    • Site-wide: 150,853
  • Since beginning of last month:
    • Site-wide: 143,025

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide